Hormonal Treatment for Prostate Cancer in Frail Patients
Author Information
Author(s): Büttner Thomas, Lossin Philipp, Latz Stefan, Jacobs Carolin, Krausewitz Philipp, Hauser Stefan
Primary Institution: University Hospital Bonn
Hypothesis
What are the effects of novel hormonal agents on survival in men with metastatic castration-resistant prostate cancer and poor performance status?
Conclusion
NHA therapy may not provide significant survival benefits for mCRPC patients with an ECOG PS of ≥2.
Supporting Evidence
- 30 patients received novel hormonal agents, while 23 chose Best Supportive Care.
- The median overall survival was 9.1 months for Best Supportive Care and 7.0 months for NHA.
- No significant differences in adverse events were observed between treatment groups.
Takeaway
This study looked at how well new hormone treatments work for older men with advanced prostate cancer who are not in great health. It found that these treatments might not help them live longer.
Methodology
The study analyzed 53 men with mCRPC and ECOG PS ≥2, comparing outcomes of those treated with NHA versus Best Supportive Care.
Potential Biases
Potential selection bias due to the single-center design and uneven distribution of treatment groups over time.
Limitations
The study is limited by its retrospective design, small sample size, and lack of standardized protocols for Best Supportive Care.
Participant Demographics
The median age of participants was 83.8 years, with the majority having an ECOG PS of 2.
Statistical Information
P-Value
0.140
Confidence Interval
95% CI: 0.85–3.20
Statistical Significance
p>0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website